NCT02658968 - Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2017

Primary Completion Date

June 4, 2021

Study Completion Date

July 10, 2021

Conditions

Relapsed, Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Betalutin

Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.

Trial Locations (10)

Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino

Sylvester Comprehensive Cancer Centre, Miami

Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento, Verona

Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna

Hospital Universitari i Politècnic La Fe, Valencia

Klinikum rechts der Isar der TU München, Munich

University of California, San Diego (UCSD) - Moores Cancer Center, San Diego

University of California, San Francisco (UCSF) - Innovation, Technology & Alliances, San Francisco

University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology Centre, Bristol

Christie NHS Foundation Trust, Manchester